Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ARTS-021 |
Trade Name | |
Synonyms | ARTS 021|ARTS021 |
Drug Descriptions |
ARTS-021 is a CDK2 inhibitor, which potentially decreases tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2568). |
DrugClasses | CDK2 Inhibitor 30 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + ARTS-021 + Fulvestrant | ARTS-021 Abemaciclib Fulvestrant | 0 | 0 |
Abemaciclib + ARTS-021 + Letrozole | ARTS-021 Abemaciclib Letrozole | 0 | 0 |
ARTS-021 | ARTS-021 | 0 | 1 |
ARTS-021 + Carboplatin | ARTS-021 Carboplatin | 0 | 1 |
ARTS-021 + Fulvestrant + Palbociclib | ARTS-021 Fulvestrant Palbociclib | 0 | 1 |
ARTS-021 + Fulvestrant + Ribociclib | ARTS-021 Fulvestrant Ribociclib | 0 | 0 |
ARTS-021 + Letrozole + Palbociclib | ARTS-021 Letrozole Palbociclib | 0 | 1 |
ARTS-021 + Letrozole + Ribociclib | ARTS-021 Letrozole Ribociclib | 0 | 0 |
ARTS-021 + Palbociclib | ARTS-021 Palbociclib | 0 | 0 |